Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Chadi Nabhan, MD, on payers using clinical pathways in hematological malignancies vs solid tumors

Dr. Nabhan, Vice President and Chief Medical Officer, Cardinal Health Specialty Solutions, on if payers are using clinical pathways in hematological malignancies the same way in solid tumors

Published: 14 December 2016

Recent Videos: ASH Conference Coverage

video

Robert Soiffer, MD, discusses ways to enhance the activity of Il-2 in chronic GVHD

Dr. Soiffer discusses ways to enhance the activity of Il-2 in chronic graft versus host disease (GVHD)

video

Andrew Lane, MD, PhD, describes the efficacy outcomes of SL-401 consolidation therapy in AML

Dr. Lane elaborates on the efficacy outcomes of SL-401 consolidation therapy in patients with acute myeloid leukemia (AML)

video

Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of BLU-285 and what makes it unique

Dr. DeAngelo provides the mechanism of action of BLU-285 and explains what makes it unique and promising

video

Daniel J. DeAngelo, MD, PhD, on the phase 1 study of BLU-285 in advanced systemic mastocytosis

Dr. DeAngelo expands on the outcomes from the phase 1 study of BLU-285 in advanced systemic mastocytosis

video

Daniel J. DeAngelo, MD, PhD, offers his opinion on the clinical development of BLU-285

Dr. DeAngelo elaborates on the clinical development of BLU-285 moving forward

video

Ching-Hon Pui, MD, on whether the FDA should accept minimal residual disease as a surrogate endpoint

Dr. Pui offers opinion on whether the FDA should accept minimal residual disease as a surrogate endpoint for regulatory approval

video

Ching-Hon Pui, MD, explains how precision medicine is changing the way pediatric ALL is treated

Dr. Pui describes how precision medicine is changing the way we treat pediatric acute lymphocytic leukemia (ALL) today

video

Ching-Hon Pui, MD, speculates on the use of CAR T-cell therapy in pediatric ALL patients

Dr. Pui tells us how he sees CAR T-cell therapy being used in pediatric acute lymphocytic leukemia (ALL) patients

video

Brad S. Kahl, MD, on the evidence for maintenance rituximab as a front-line treatment option in FLL

Dr. Kahl elaborates on the evidence for using rituximab maintenance as a front-line treatment option with bendamustine-rituxan in follicular lymphoma ...

video

Jorge Cortes, MD, shares data presented at ASH 2017 regarding bosutinib in CML treatment

Dr. Cortes tells us about the clinical data presented at ASH 2017 regarding treatment of front-line chronic myelogenous leukemia (CML) ...

Related Videos

video-image

Daniel J. DeAngelo, MD, PhD, offers his opinion on the clinical development of BLU-285

video-image

Daniel J. DeAngelo, MD, PhD, on the phase 1 study of BLU-285 in advanced systemic mastocytosis

video-image

Daniel J. DeAngelo, MD, PhD, discusses the mechanism of action of BLU-285 and what makes it unique

video-image

Andrew Lane, MD, PhD, describes the efficacy outcomes of SL-401 consolidation therapy in AML

video-image

Robert Soiffer, MD, discusses ways to enhance the activity of Il-2 in chronic GVHD

video-image

Ching-Hon Pui, MD, speculates on the use of CAR T-cell therapy in pediatric ALL patients

video-image

Ching-Hon Pui, MD, explains how precision medicine is changing the way pediatric ALL is treated

video-image

Ching-Hon Pui, MD, on whether the FDA should accept minimal residual disease as a surrogate endpoint

video-image

Ching-Hon Pui, MD, discusses minimal residual disease in pediatric and adult ALL patients

video-image

Jesus San-Miguel, MD, on the role of daratumumab in the front-line setting in multiple myeloma (MM)

video-image

Jorge Cortes, MD, shares data presented at ASH 2017 regarding bosutinib in CML treatment

video-image

Brad S. Kahl, MD, on the evidence for maintenance rituximab as a front-line treatment option in FLL

video-image

James R. Downing, MD, explains the mission of St. Jude Children’s Research Hospital

video-image

Andrew Lane, MD, PhD, on how frequently clinicians interact with frail AML patients

video-image

Andrew Lane, MD, PhD, on treatment approaches when managing frail AML patients

video-image

Andrew Lane, MD, PhD, offers strategies for clinicians when treating frail AML patient populations

video-image

Andrew Lane, MD, PhD, shares outcomes from the phase 2 study of SL-401 in patients with BPDCN

video-image

Jesus San-Miguel, MD, on daratumumab in a first-line setting as a result of the ALCYON study

video-image

Jesus San-Miguel, MD, explains the efficacy and safety outcomes of the ALCYON clinical study

video-image

Jens G. Lohr, MD, PhD, discusses the kind of information we can gather from liquid biopsy

video-image

Jens G. Lohr, MD, PhD, on utilizing liquid biopsy and how it compares to bone marrow biopsy

video-image

James Essell, MD, discusses the concerns for patients receiving allogeneic transplantations

video-image

James Essell, MD, on how allogeneic transplantation is incorporated into hematologic malignancy

video-image

Brad S. Kahl, MD, considers the unmet medical needs in treatment of Hodgkin lymphoma

video-image

Brad S. Kahl, MD, discusses the ECHELON-1 phase 3 clinical trial in Hodgkin lymphoma

video-image

Brad S. Kahl, MD, tells us about his study evaluating ADCT-402 in DLBCL

video-image

Jorge Cortes, MD, on how generic imatinib is being adopted as an alternative to branded imatinib

video-image

Jorge Cortes, MD, on what was discussed at ASH 2017 regarding treatment discontinuation in AML

video-image

Simon Rule, MD, considers the clinical development plan with Imbruvica in mantle cell lymphoma (MCL)

video-image

Simon Rule, MD, discusses the ibrutinib data in relapsed/refractory MCL presented at ASH 2017

video-image

Edward A. Copelan, MD, shares highlights from ASH 2017 regarding treatment of acute myeloid leukemia

video-image

Edward A. Copelan, MD, on allogeneic transplantation & CAR T-cell therapy in lymphoma and myeloma

video-image

Edward A. Copelan, MD, considers whether azacitidine can be used for induction in AML

video-image

James R. Downing, MD, discusses the significant studies presented at ASH 2017

video-image

James R. Downing, MD, on the evolution of St. Jude Children’s Research Hospital

video-image

John Burke, MD, on rituximab as an effective strategy after 1st line bendamustine-rituximab in FL

video-image

Keith Pratz, MD, on the proportion of AML patients who fall into the frail category

video-image

Keith Pratz, MD, explains how he is incorporating Vyxeos into his treatment of AML patients

video-image

Keith Pratz, MD, suggests strategies for clinicians when treating frail AML patients

video-image

Keith Pratz, MD, on exciting clinical data regarding FTL3 tyrosine kinase inhibitors in AML patients

video-image

Keith Pratz, MD, shares the outcome of the venetoclax study in treatment-naive AML patients

video-image

Keith Pratz, MD, on combining ivosidenib or enasidenib with chemotherapy in AML

video-image

Keith Pratz, MD, tells us about the epidemiology and cytogenetic risk associated with AML

video-image

Fredrick B. Hagemeister, MD, on the exploration of CAR T-cell therapies in various lymphoma types

video-image

Fredrick B. Hagemeister, MD, describes how PD-1 inhibitors are being incorporated into FL treatment

video-image

Fredrick B. Hagemeister, MD, on managing toxicities associated with CAR T-cell therapies

video-image

Fredrick B. Hagemeister, MD, on what we should know about CAR T-cell therapies

video-image

Andrew Lane, MD, PhD, on minimal residual disease and AML treatment decisions

video-image

John Burke, MD, lists the top findings from ASH 2017 regarding lymphoid malignancies

video-image

John Burke, MD, on combination atezolizumab, obinutuzumab, and bendamustine in follicular lymphoma

video-image

Habte Yimer, MD, on daratumumab, cyclophosphamide, bortezomib, & dexamethasone in relapsed MM

video-image

Habte Yimer, MD, considers the impact of combination obinutuzumab and bendamustine on CLL patients

video-image

Martin Hutchings, MD, details the role of PET in the management of Hodgkin’s lymphoma

video-image

Martin Hutchings, MD, considers how the ECHELON-1 study could be practice changing

video-image

Eunice Wang, MD, shares exciting data for acute myeloid leukemia (AML) presented at ASH 2017

video-image

Eunice Wang, MD, considers approaches for clinicians when managing frail AML patients

video-image

Eunice Wang, MD, on incorporating Vyxeos (liposomal daunorubicin and cytarabine) in AML treatment

video-image

Eunice Wang, MD, on strategies for frail AML patients who do not qualify for intensive therapy

video-image

Eunice Wang, MD, on how minimal residual disease is being integrated into treatment decisions in AML

video-image

Michael Boxer, MD, on the effectiveness of fostamatinib in the maintenance of ITP responses

video-image

Parameswaran Hari, MD, MRCP, MS, considers the remaining unmet medical needs in MM

video-image

Parameswaran Hari, MD, MRCP, MS, discusses the clinical relevance of minimal residual disease

video-image

Parameswaran Hari, MD, MRCP, MS, provides an update on how MM patients are staged at diagnosis

video-image

Parameswaran Hari, MD, MRCP, MS, on promising cellular immunotherapy studies from ASH 2017

video-image

Parameswaran Hari, MD, MRCP, MS, on how the field of immunotherapy is evolving for MM patients

video-image

Parameswaran Hari, MD, MRCP, MS, on checkpoint inhibitors and MM treatment algorithms

video-image

David Miklos, MD, PhD, on the possible combination of ibrutinib and CAR T-cell therapies

video-image

David Miklos, MD, PhD, explains how ibrutinib is being studied for the treatment of GVHD

video-image

David Miklos, MD, PhD, describes the optimal way to use ibrutinib in the treatment of GVHD

video-image

David Miklos, MD, PhD, on the outcomes of the ZUMA-1 clinical study

video-image

Michael Boxer, MD, on how obinutuzumab and bendamustine impacts quality of life in CLL patients

video-image

Michael Boxer, MD, considers broader uses for fostamatinib

video-image

Paul Richardson, MD, on the importance of real world evidence (RWE)

video-image

Paul Richardson, MD, shares the efficacy outcomes of GSK-916 in relapsed/refractory MM patients

video-image

Paul Richardson, MD, on adding CAR T-cell therapy to multiple myeloma treatment algorithms

video-image

Robert Soiffer, MD, on other applications that IL-2 might have outside of treating chronic GVHD

video-image

Robert Soiffer, MD, on some of the innovative approaches to treating chronic GVHD

video-image

Robert Soiffer, MD, discusses current treatments available for chronic GVHD

video-image

Robert Soiffer, MD, explains GVHD and some of the complications that come along with it

video-image

Jane N. Winter, MD, discusses how CAR T-Cell therapies will impact the treatment of lymphomas

video-image

Jane N. Winter, MD, shares the clinical evidence supporting brentuximab vedotin in older patients

video-image

Jane N. Winter, MD, on whether checkpoint inhibitors can be used effectively in Hodgkin’s Lymphoma

video-image

Jane N. Winter, MD, explains how PD-1 and PD-L1 expression changes the way DLBCL is treated

video-image

Robert M. Rifkin, MD, on excluding transplantation from MM treatment algorithms

video-image

Robert M. Rifkin, MD, discusses if COMPASS is close to its goal of achieving whole genome sequencing

video-image

Robert M. Rifkin, MD, on the Connect Multiple Myeloma patient registry improving characterization

video-image

Robert M. Rifkin, MD, on how the Connect Multiple Myeloma patient registry is helping patients

video-image

Andre Goy, MD, tells us about the long-term outcomes of the ZUMA-1 trial

video-image

Andre Goy, MD tells us about the BTK combination with lenalidomide in MCL

video-image

Andre Goy, MD, discusses the best strategy for using ibrutinib in MCL

video-image

David S. Siegel, MD, shares his thoughts on the most exciting clinical trial presented at ASH 2017

video-image

David S. Siegel, MD, discusses proteasome inhibitors and Multiple Myeloma

video-image

David S. Siegel, MD, discusses how stem cell transplant figures into MM treatment algorithms

video-image

David S. Siegel, MD, on how molecular profiling is helping drive treatment strategies

video-image

C. Ola Landgren, MD, discusses remaining major unmet medical needs for MM

video-image

C. Ola Landgren, MD, discusses risk factors for developing AML or MDS after treatment of MM

video-image

C. Ola Landgren, MD, discusses continuous therapy vs fixed duration therapy in MM patients

video-image

C. Ola Landgren, MD, on MRD as a legitimate surrogate endpoint in multiple myeloma clinical trials

video-image

John Gerecitano, MD, discusses the medical unmet needs in the treatment of follicular lymphoma

video-image

John Gerecitano, MD, on what genetic predictors of response we have for follicular lymphoma

video-image

John Gerecitano, MD, discusses how PET staging affects outcomes and prognosis of follicular lymphoma

video-image

John Gerecitano, MD, on predictors of response to tazemetostat in diffuse large B-cell lymphoma

video-image

John Gerecitano, MD, talks about tazemetostat’s class and mechanism of action

video-image

Miles Prince, MD, discusses I-O compounds and T-Cell Lymphoma treatment algorithms

video-image

Miles Prince, MD, on which emerging compounds for T-Cell Lymphomas look promising

video-image

Miles Prince, MD, on the challenges to recruit and accrue patients to rare-cancer clinical studies

video-image

Miles Prince, MD, discusses the efficacy and safety of brentuximab vedotin to treat CTCL patients

video-image

Miles Prince, MD, on the role CD30 plays when selecting a treatment algorithm for CTCL patients

video-image

Miles Prince, MD, on the concerns when choosing a treatment plan for newly diagnosed CTCL patients

video-image

Sattva Neelapu, MD, on novel agents and up-front approaches showing efficacy in lymphomas

video-image

Sattva Neelapu, MD, shares his approach to optimizing CAR T-Cell therapies

video-image

Sattva Neelapu, MD, discusses efficacy results of the ZUMA-1 trial

video-image

John P. Leonard, MD, on the role social media plays in medicine

video-image

John P. Leonard, MD, on CAR-T cell therapies being developed for the treatment of lymphomas

video-image

John P. Leonard, MD, on the role checkpoint inhibitors play in lymphoma treatment algorithms

video-image

John P. Leonard, MD, discusses novel agents for treating aggressive lymphomas

video-image

Gary Gordon, MD, PhD, on MRD endpoint for outcomes in the MURANO study

video-image

Gary Gordon, MD, PhD, discusses safety concerns in the phase 3 MURANO clinical trial

video-image

Gary Gordon, MD, PhD, discusses efficacy results of the phase 3 MURANO clinical trial

video-image

Matthew Davids, MD, on how checkpoint inhibitors are being developed for hematologic malignancies

video-image

Sagar Lonial MD, FACP, on expectations for response in the challenging patient type

video-image

Sagar Lonial MD, FACP, on MM patients not responding to monotherapy and combination regimens

video-image

Sagar Lonial MD, FACP, discusses unmet need for multiple myeloma patients

video-image

Sagar Lonial MD, FACP, on predicting venetoclax sensitivity in MM using biologic active assays

video-image

Bruce D. Cheson, MD, on the role of nivolumab in Hodgkin Lymphoma

video-image

Bruce D. Cheson, MD, discusses care, toxicities, and outcomes treating CLL patients with venetoclax

video-image

Bruce D. Cheson, MD on choosing a front-line therapeutic regimen for CLL patients

video-image

Sattva Neelapu, MD shares his advice for sites that are new to treating with CAR T-Cell therapies

video-image

Sattva Neelapu, MD shares safety results of the ZUMA-1 trial in patients with NHL

video-image

Matthew Davids, MD discusses his study using ibrutinib plus FCR in younger CLL patients

video-image

Matthew Davids, MD discusses how he typically treats front line CLL outside of a clinical study

video-image

John P. Leonard, MD discusses improving outcomes in high risk follicular lymphoma patients

video-image

Sagar Lonial MD, FACP tells us about the immunomodulatory mechanism of action of daratumumab

video-image

Sagar Lonial MD, FACP on whether relapsed multiple myeloma patients should be profiled molecularly

video-image

Bruce D. Cheson, MD discusses the efficacy and safety of acalabrutinib in relapsed/refractory MCL

video-image

John P. Leonard, MD discusses lenalidomide plus rituximab for the treatment of MCL

video-image

Ted Okon, MBA, speculates on the path forward regarding 340B policy

video-image

Ted Okon, MBA, on the impact of the reduction in reimbursement for hospitals participating in 340B

video-image

Jeff Mortier speculates on the future of 340B policy

video-image

Jeff Mortier considers how 340B is impacting community oncology

video-image

Fred Schnell, MD, explains what COA is doing to help practices succeed in the OCM

video-image

Suanne Gersdorf, FACHE, MSB, shares how 340B has impacted her practice

video-image

Melissa Johnson, MD, on how Next Generation Sequencing is relevant to the treatment of NSCLC

video-image

Jennie Crews, MD, MMM, FACP, on the influence of MIPS & MACRA at Seattle Cancer Care Alliance

video-image

Satish Shah, MD, on how technology can ease the burden of reporting quality measures

video-image

Kavita Patel, MD, MS, FACP, discusses how 340B has impacted her practice

video-image

Kavita Patel, MD, MS, FACP, regarding the impact of MACRA on payment reform

video-image

Stephen Grubbs, MD, considers how MIPS & MACRA are transforming the delivery of cancer care

video-image

Stephen Grubbs, MD, describes the tools ASCO provides to help practices move toward value-based care

video-image

Stephen Grubbs, MD, on what ASCO is doing to help educate members about MIPS & MACRA

video-image

Bobby Green, MD, analyzes the role of health technology companies in the design of APMs

video-image

Ann Marie Edwards on how patients have been impacted by value-based care

video-image

Ann Marie Edwards tells us how technology has impacted the delivery of value-based care

video-image

Ann Marie Edwards examines how 340B has impacted Alliance Cancer Specialists

video-image

Ann Marie Edwards considers the physician practice models poised to succeed in a value-based world

video-image

George Daneker, MD, on the role of CMS and commercial payers in delivering value-based care

video-image

George Daneker, MD, regarding the role of consistency in the delivery of high-quality care

video-image

Jennie Crews, MD, MMM, FACP, on embracing new value-based oncology models

video-image

Jennie Crews, MD, MMM, FACP, explains how to maintain the delivery of quality cancer care

video-image

Sibel Blau, MD, discusses how 340B has impacted Northwest Medical Specialties

video-image

Sibel Blau, MD, shares how her practice has transformed in order to participate in MACRA

video-image

Roy Beveridge, MD, regarding the most cost-efficient alternative payment models

video-image

Patricia Goldsmith shares what CancerCare is doing to help patients with financial toxicity

video-image

Nicholas J. Vogelzang, MD, FASCO, FACP, speculates on the cost implications of abiraterone

video-image

Randall Oyer, MD, describes how ACCC is supporting practices that are participating in OCM

video-image

Randall Oyer, MD, reveals the challenges and solutions his practice is finding as a result of OCM

video-image

Randall Oyer, MD, shares major themes emerging from the OCM

video-image

Randall Oyer, MD, on how OCM is helping the healthcare system transition from volume to value

video-image

Leonard Saltz, MD, elaborates on what interventions could help alleviate financial toxicity

video-image

Leonard Saltz, MD, on how to begin the conversation with patients about financial toxicity

video-image

Andrew Pecora, MD, FACP, CPE, on the implications of healthcare and reimbursement reform

video-image

Andrew Pecora, MD, FACP, CPE, describes the movement to value-based reimbursement

video-image

Andrew Pecora, MD, FACP, CPE, on healthcare reform and the move from volume to value in oncology

video-image

Debra Patt, MD, MPH, MBA, speculates on upcoming changes in the 340B program

video-image

Lucio Gordan, MD, shares his concerns with PBMs as they affect community oncology practices

video-image

David Eagle, MD, shares how his small practice is successful in today’s oncology environment

video-image

David Eagle, MD, compares the rate of oncology spending to rate of total healthcare spending

video-image

David Eagle, MD, evaluates what part of total oncology care spending is drug spending

video-image

Joseph Lynch, MD, on why independent community oncology practices join hospital systems

video-image

Skip Burris, MD, shares how clinical pathways impact prescribing decisions

video-image

Skip Burris, MD, on the impact of OCM on large community practices

video-image

Bruce Feinberg, DO, on what community oncologists should consider with MACRA, MIP’s and OCM

video-image

Jeff Patton, MD, shares how clinical pathways help with value-based efforts

video-image

Jeff Patton, MD, on whether the Oncology Care Model impacts the prescribing of oral cancer agents

video-image

Jeff Patton, MD, explains how Tennessee Oncology has transformed to participate in OCM

video-image

Lucio Gordan, MD, considers how 340B is impacting physicians and practices

video-image

Robert Baird Jr. reflects on how his practice has changed as a result of OCM

video-image

Edward Li on how clinical pathways are making progress towards their original goals

video-image

Edward Li reflects on how pathways have impacted oncology treatment over the last 5 years

video-image

Ted Okon lists key takeaways from the 2017 COA meeting

video-image

Ted Okon describes how PBMs affect oncologists and cancer patients

video-image

Ted Okon shares the latest news on the 340B policy

video-image

Ben Jones gives advice to practices interested in advocating for community oncology

video-image

Lalan Wilfong, MD, shares lessons from his experience participating in OCM

video-image

Lalan Wilfong, MD, explains how OCM has impacted cancer patients in his practice

video-image

Lalan Wilfong, MD, provides opinion on how OCM is changing his practice

video-image

Debra Patt, MD, considers how community oncology contributes to clinical research advancement

video-image

Debra Patt, MD, on technological advances in cancer care and community oncology

video-image

Debra Patt, MD, shares how community oncology has contributed to advances in population health

video-image

Debra Patt, MD, elaborates on how community oncology contributes to the Cancer Moonshot

video-image

Jeff Vacirca, MD, shares how COA is addressing the DIR fees coming from PBMs

video-image

Jeff Vacirca, MD, on COA’s efforts to represent community oncologists

video-image

Jeff Vacirca, MD, discusses DIR fees and how COA hopes to solve the PBM fee problem

video-image

Jeff Vacirca, MD, on how COA is addressing Part B concerns among community oncologists

video-image

Lucio Gordan, MD, on how community oncology practices can utilize their own data

video-image

Lucio Gordan, MD, reflects on how he sees community oncology using big data

video-image

Matt Farber provides insight on the evolution of specialty pharmacies

video-image

Matt Farber explains the role of specialty pharmacy in delivering quality cancer care

video-image

David Eagle, MD, compares small, community oncology practices with large practices and hospitals

video-image

Ray Bailey on how participation in OCM impacts the in-house pharmacy at FCS

video-image

Patrick Cobb, MD, on cancer care costs in hospital outpatient and community settings

video-image

Brad Prechtl offers his opinion on how size influences community oncology practices

video-image

William Harwin, MD, on how clinical pathways impact treatment decisions at FCS

video-image

William Harwin, MD, explains how he manages the quality measures required for OCM

video-image

William Harwin, MD, on working with local payers to deliver quality care

video-image

William Harwin, MD, talks changes at Florida Cancer Specialists since participating in OCM

video-image

Barbara McAneny, MD, discusses 1 sided and 2 sided risk associated with participation in the OCM

video-image

Barbara McAneny, MD, shares her concerns with the way OCM is progressing at this point

video-image

Ricky Newton tells us how COA is addressing the PBM DIR fees and helping community oncology

video-image

Bobby Green, MD, on how oncologists can leverage data to understand real quality care

video-image

Barbara McAneny, MD, explains how the AMA and community oncology should interact